Dry powder inhalation formulations and their use for treating lung

By using dry powder inhalation formulations that combine triglycerides such as monohydroxystearin with active drugs, the problems of short residence time and poor release curve of dry powder inhalation formulations in the lungs are solved, and more efficient drug deposition and release are achieved , improves the effectiveness and tolerance of treatment.

CN113271960BActive Publication Date: 2024-11-05VRIJE UNIV BRUSSEL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980086456.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-12-28
Filing Date
2019-12-27
Publication Date
2024-11-05
Estimated Expiration
2039-12-27

AI Technical Summary

Technical Problem

Existing dry powder inhalation formulations have a short residence time in the lungs, resulting in the need for multiple doses, and may cause adverse local tolerance due to rapid dissolution and high peak concentrations, and conventional triglycerides are ineffective against drug release profiles, limiting the Effectiveness of lung treatment.

Method used

Triglycerides containing monohydroxystearin, dihydroxystearin, trihydroxystearin and mixtures are used as lipid matrix, combined with active pharmaceutical ingredients, adjust the ratio of API to triglycerides to form suitable lipids Matrix, dry powder inhalation formulations are prepared by spray dry drying or extrusion technology, improving the pulmonary deposition rate and release profile.

Benefits of technology

It significantly improves the deposition rate and release curve of the drug in the lungs, extends the retention time of the drug in the lungs, improves the effectiveness and tolerance of the treatment, reduces systemic distribution, and reduces adverse reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113271960B_ABST
    Figure CN113271960B_ABST
Patent Text Reader

Abstract

The present invention relates to a dry powder inhalation formulation comprising at least one API and a lipid matrix comprising at least one triglyceride selected from the group consisting of monohydroxystearin, dihydroxystearin, trihydroxystearin and mixtures thereof, and a method for preparing the same.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to dry powder inhalation formulations and their use for treating the lungs.

[0002] Dry powder inhalation (DPI) therapy is now predominantly used to deliver many treatments to the lungs, for example in the treatment of asthma, and many efforts have been made to optimize DPI formulations to prolong retention of the active pharmaceutical ingredient (API) in the lungs.

[0003] Inhalation allows high drug doses to be administered directly to the lungs without prior distribution in the organism. On the one hand, this allows smaller amounts of active pharmaceutical ingredients (API) to be used and potentially wasted in the organism, and, moreover, when the toxicity of the API is considered, direct in situ administration allows for reduced toxicity.

[0004] Furthermore, since the lungs are characterized by a large absorptive surface, inhalation is a promising administration route for delivering APIs to the systemic circulation.

[0005] However, conventional immediate-release dry powder inhalation (DPI) formulations may still result in too short a residence in the lungs due to multiple clearance mechanisms for exogenous inhaled particles (i.e., mucociliary and macrophage clearance) and rapid dissolution of drug particles leading to rapid absorption into the systemic circulation. Therefore, this short residence requires multiple dosing, resulting in poor patient compliance. Immediate release of the API may also result in poor local tolerance due to rapid dissolution of drug particles and high peak concentrations of API in the lung fluid after lung deposition.

[0006] Specific excipients have been identified to prolong the retention of the API in the lung with a sustainable retention profile in the lung.

[0007] Therefore, further development of dry powder inhalation formulations is needed to increase the effectiveness of pulmonary treatment.

[0008] In this case, for example, a controlled-release DPI formulation based on cisplatin with high drug load and high fine particle fraction was developed (Levet et al., Int J Pharm 2016). The formulation has controlled release and prolonged lung retention, resulting in low systemic distribution (Levet et al., Int J Pharm 2017).

[0009] To this end, Levet et al. have studied a specific formulation of an antineoplastic agent, namely cisplatin, containing a PEGylated excipient to avoid too rapid clearance by the lung epithelial defense mechanisms and also compared different carriers, such as polymers and lipid matrices, to allow for a prolonged retention time in the lungs and thus increase the inhalation efficiency.

[0010] The lipid matrix described in the work of Levet et al. comprises, among others, tristearin, which was identified as a promising candidate for providing a lipid matrix.

[0011] Furthermore, even though lipid-derived excipients for matrix formation are preferred over polymers for toxicity reasons, only a few substances capable of forming lipid matrices are permitted and accepted for pharmaceutical compositions to be inhaled compared to other therapeutic treatment routes (Pilcer et Amighi, Int J Pharm 2010).

[0012] Unfortunately, although tristearin was identified as a promising candidate, its availability as a pharmaceutical compound in the market is rather limited.

[0013] The present invention addresses at least some of these disadvantages by providing a dry powder inhalation formulation, e.g., for monotherapy or multitherapy, comprising at least one active pharmaceutical ingredient (API) and a lipid matrix comprising at least one triglyceride selected from the group consisting of monohydroxystearin, dihydroxystearin, trihydroxystearin, and mixtures thereof.

[0014] It has surprisingly been determined that the at least one triglyceride selected from the group comprising monohydroxystearin, dihydroxystearin, trihydroxystearin and mixtures thereof, which is present in pharmaceutical grade, is able to form a lipid matrix with the API (Active Pharmaceutical Ingredient) and shows an increased lung deposition rate in the lungs, the latter allowing for pulmonary inhalation.

[0015] Indeed, monohydroxystearin, dihydroxystearin, trihydroxystearin and mixtures thereof are compounds having physicochemical properties such as a LogP value higher than 5, preferably between 14 and 25, more particularly between 18 and 25 and preferably about 20, as measured using the shake flask method and / or a melting point temperature higher than or equal to 40°C, preferably higher than or equal to 60°C, more preferably higher than or equal to 75°C.

[0016] This allows the production of an inhalation formulation in dry powder form and which is neither an oily phase nor a viscous paste, suitable for use in a dry powder inhaler.

[0017] Furthermore, according to the present invention, contrary to all expectations, it has been determined that by varying the ratio between the amount of API and the amount of at least one triglyceride selected from the group comprising monohydroxystearin, dihydroxystearin, trihydroxystearin and mixtures thereof, it is possible to increase the pulmonary deposition rate of the API relative to other conventional triglycerides, such as tristearin, and to provide a modulated dissolution profile of the API, which is not the case with conventional triglycerides.

[0018] Preferably, the weight ratio between the at least one API and the at least one triglyceride of the dry powder inhalation formulation according to the invention is: API / triglyceride is 0.1 / 99.9 to 99.9 / 0.1, preferably 10 / 90 to 88 / 12, preferably 15 / 85 to 85 / 15, preferably 25 / 75 to 75 / 25, more preferably 30 / 70 to 70 / 30, in particular 40 / 60 to 60 / 40, for example about 50 / 50.

[0019] Advantageously, in the formulation according to the invention, the at least one triglyceride is hydrogenated castor oil.

[0020] Castor oil has been described in the literature in a long list of common excipients (see US 2005 / 0042178) or grinding aids (WO 2013 / 128283).

[0021] In a preferred embodiment according to the present invention, the dry powder inhalation formulation comprises 0.1 wt% to 98 wt% of the at least one API relative to the total weight of the dry powder inhalation formulation. In a first specific embodiment according to the present invention, the active agent is a small chemical molecule having a solubility in alcohol of at least 0.1 w% / v, or at least 0.5 w% / v, more preferably at least 1 w% / v, more particularly at least 5 w% / v. According to this first specific embodiment, the small chemical molecule is any active pharmaceutical ingredient (API) having a solubility in alcohol of 0.1% w / v or more, which is defined as an alcohol-soluble API in the present invention, such as budesonide, paclitaxel, pemetrexed, itraconazole, voriconazole, clarithromycin, salbutamol, salbutamol sulfate, fluticasone, beclomethasone, mometasone, mometasone furoate, ciclesonide, formoterol, aformoterol, indacaterol, indacaterol maleate, olodaterol, olodaterol hydrochloride, salmeterol, ipratropium bromide, glycopyrrolate, tiotropium bromide, umeclidinium bromide, ibuprofen, vancomycin, vancomycin hydrochloride, tetrahydroliprostine, isoniazid, rifampicin, pyrazinamide, docetaxel, vincristine, vincristine sulfate, etoposide, vinorelbine, gemcitabine, etc.

[0022] More specifically, the dry powder inhalation formulation according to the first specific embodiment contains 0.1 wt% to 95 wt%, preferably 1 wt% to 90 wt%, more preferably 1 wt% to 85 wt% of the at least one API, relative to the weight of the dry powder inhalation formulation.

[0023] In a preferred embodiment according to the present invention, the dry powder inhalation formulation consists of lipid matrix particles in which the alcohol-soluble API is dissolved or finely dispersed.

[0024] In a second specific embodiment according to the present invention, the active agent is a small chemical molecule with a solubility in alcohol of less than 0.5 w% / v. In this second specific embodiment, the small chemical molecule is any API with a solubility in alcohol of less than 0.5% w / v, particularly less than 0.1% w / v, more particularly less than 0.01% w / v, which is defined as an alcohol-insoluble API, such as cisplatin, carboplatin, oxaliplatin, pemetrexed disodium, azacytidine, beclomethasone dipropionate, tobramycin, aclidinium bromide, etc.

[0025] More specifically, the dry powder inhalation formulation according to the second specific embodiment contains 0.1 wt% to 95 wt%, preferably 1 wt% to 90 wt%, more preferably 1 wt% to 85 wt% of the at least one API, relative to the weight of the dry powder inhalation formulation.

[0026] Therefore, the dry powder inhalation formulation comprises 0.1 wt% to 95 wt%, preferably 1 wt% to 90 wt%, more preferably 1 wt% to 85 wt%, for example 1 wt% to 60 wt% or 1 wt% to 50 wt% of the alcohol-insoluble API relative to the total weight of the dry powder inhalation formulation.

[0027] In a preferred embodiment of the present invention, the dry powder inhalation formulation consists of lipid matrix particles in which the alcohol-insoluble API is dispersed.

[0028] In a third specific embodiment according to the present invention, the active agent is a macromolecule. In this third specific embodiment according to the present invention, the dry powder inhalation formulation contains 0.1 wt% to 95 wt%, preferably 1 wt% to 90 wt%, more preferably 1 wt% to 85 wt% of the at least one API relative to the weight of the dry powder inhalation formulation.

[0029] Therefore, the dry powder inhalation formulation comprises 0.1 wt% to 95 wt%, preferably 1 wt% to 90 wt%, more preferably 1 wt% to 85 wt%, for example 1 wt% to 60 wt% or 1 wt% to 50 wt% of the macromolecule relative to the total weight of the dry powder inhalation formulation.

[0030] In another preferred embodiment, the formulation according to the invention further comprises an excipient that prolongs lung retention, such as a pegylated excipient or a polysaccharide, such as chitosan or dextran.

[0031] Preferably, according to the present invention, the extended lung retention excipient is a pegylated excipient and is present in an amount of 0.1 wt% to 20 wt%, preferably 0.2 wt% to 10 wt%, more preferably 0.5 wt% to 5 wt% relative to the total weight of the dry powder inhalation formulation.

[0032] More particularly, according to the present invention, the PEGylated excipient is derived from vitamin E or phospholipids, such as tocopheryl polyethylene glycol succinate (TPGS) or distearoylphosphoethanolamine polyethylene glycol 2000 (DSPE-mPEG-2000).

[0033] In another preferred embodiment, the formulation according to the invention further comprises one or more excipients, for example excipients that improve the physicochemical and / or aerodynamic properties of the dry powder for inhalation.

[0034] The term "one or more excipients" refers to compounds selected from the group consisting of sugar alcohols; polyols (e.g., sorbitol, mannitol, and xylitol); crystalline sugars, including monosaccharides (e.g., glucose, arabinose) and disaccharides (e.g., lactose, maltose, sucrose, dextrose, trehalose, maltitol); inorganic salts (e.g., sodium chloride and calcium carbonate); organic salts (e.g., sodium lactate, potassium phosphate or sodium phosphate, sodium citrate, urea); polysaccharides (e.g., dextran, chitosan, starch, cellulose, hyaluronic acid and its derivatives); oligosaccharides (e.g., cyclodextrin and dextrin); titanium dioxide; silicon dioxide; magnesium stearate; lecithin; amino acids (e.g., leucine, isoflavones, oligosaccharides ... leucine, histidine, threonine, lysine, valine, methionine, phenylalanine); amino acid derivatives (e.g., acesulfame potassium, aspartame); lauric acid or derivatives (e.g., esters and salts); palmitic acid or derivatives (e.g., esters and salts); stearic acid or derivatives (e.g., esters and salts); erucic acid or derivatives (e.g., esters and salts); behenic acid or derivatives (e.g., esters and salts); sodium stearoyl fumarate; sodium stearoyl lactylate; phosphatidylcholine; phosphatidylglycerol; natural and synthetic lung surfactants; lauric acid and its salts (e.g., sodium lauryl sulfate, magnesium lauryl sulfate); triglycerides; sugar esters; phospholipids; cholesterol; talc.

[0035] In certain preferred embodiments, the excipient is mannitol, dextrose or lactose.

[0036] In certain preferred embodiments, the excipient is a phospholipid or cholesterol.

[0037] In certain preferred embodiments, the excipient is mannitol, dextrose, hyaluronic acid, lactose, phospholipids or cholesterol.

[0038] In certain preferred embodiments, the excipient is mannitol, dextrose, phospholipids or cholesterol.

[0039] In certain embodiments, the at least one excipient is a carrier.

[0040] In a preferred embodiment of the formulation of the present invention, the formulation has a geometric particle size distribution (PSD) d less than or equal to 30 μm, preferably less than 15 μm, preferably less than or equal to 10 μm, preferably less than or equal to 5 μm.50 in the form of fine particles.

[0041] In another preferred embodiment of the formulation according to the present invention, the formulation is a formulation having a geometric particle size distribution (PSD) d less than or equal to 60 μm, preferably less than or equal to 30 μm, more preferably less than or equal to 15 μm, preferably less than or equal to 10 μm and more preferably less than or equal to 7 μm. 90 in the form of fine particles.

[0042] In another preferred embodiment of the formulation according to the invention, the formulation is in the form of particles having a volume average diameter D[4,3] of less than or equal to 40 μm, preferably less than or equal to 20 μm, more preferably less than or equal to 15 μm, preferably less than or equal to 10 μm, preferably less than or equal to 6 μm.

[0043] Preferably, according to the present invention, the improved excipient and / or the excipient is present in an amount of 0.1 wt% to 80 wt%, preferably less than 70 wt%, more preferably less than 60 wt%, in particular less than 50 wt%, for example less than 50 wt%, relative to the total weight of the dry powder inhalation formulation.

[0044] The term "fine particle dose" or "FPD" generally refers to the mass of particles having an aerodynamic diameter below 5 μm relative to the mass of the nominal dose (ie the mass of the dose loaded into the inhalation device).

[0045] The fine particle dose or fine particle fraction represents the fraction of a drug formulation that can be deeply inhaled and, in theory, is available for pharmacological activity (Dunbar et al., Kona 16:7-45, 1998).

[0046] In an advantageous embodiment according to the invention, the formulation is in the form of fine particles having a mass median aerodynamic diameter (MMAD) less than or equal to 6 μm, preferably less than or equal to 5 μm, preferably less than or equal to 4 μm.

[0047] MMAD refers to the diameter of particles deposited in the impactor, where 50% (w / w) of the particles have a smaller diameter and 50% (w / w) have a larger diameter.

[0048] The term "aerodynamic diameter" or "dae" of a particle can be defined as the diameter of a sphere of unit density (i.e., density 1) which has the same settling velocity in still air as the particle in question. "dae" provides a useful measure of inhalable particles and takes into account factors that affect their aerodynamic properties. "dae" can be used to compare particles of different physical sizes and take into account their density and shape as well as their geometric dimensions.

[0049] The methods used to measure "dae" are those described in the European or US Pharmacopoeia using an impactor or impaction device, such as a glass impactor, a multistage liquid impactor (MsLI), an Anderson cascade impactor, or a next generation impactor (NGI). These allow the measurement of aerodynamic properties of DPI formulations (including MMAD, geometric standard deviation, lung deposition pattern, fine particle dose, fine particle fraction) under simulated respiratory conditions.

[0050] The total dose of particles with an aerodynamic diameter less than 5 μm can be calculated from the collection efficiency curve by interpolation and is considered the fine particle dose (FPD) or fine particle fraction (FPF), expressed as a percentage of the nominal API dose (i.e., the dose contained in the DPI device).

[0051] Preferably, the dry powder inhalation formulation according to the present invention is packaged in, for example, blisters or capsules for use in a dry powder inhaler or a sealed and / or disposable dry powder inhaler.

[0052] In a specific embodiment, the active agent is a small chemical molecule having bronchodilator activity, glucocorticoid activity, anti-inflammatory activity, anti-infective activity (e.g., antibiotic, anti-tuberculosis, anti-fungal, anti-viral), etc. ...

[0053] In another specific embodiment, the small chemical molecule is any active pharmaceutical ingredient absorbed by the lungs for systemic or local treatment, such as budesonide, salbutamol, fluticasone, beclomethasone, mometasone, ciclesonide, formoterol, salbutamol, arformoterol, indacaterol, olodaterol, salmeterol, ipratropium, aclidinium, glycopyrronium, tiotropium bromide, umeclidinium bromide, mometasone, ciclesonide, formoterol, arformoterol, ibuprofen, tobramycin, vancomycin, tetrahydrolipostine, clarithromycin, isoniazid, rifampicin, pyrazinamide, itraconazole, voriconazole, aztreonam, ethambutol, streptomycin, styrene ... amikacin, kanamycin, amikacin, colistin, polymyxin E mesylate sodium, ramycin, ciprofloxacin, rifapentine, doxycycline, cycloserine E, ethionamide, gatifloxacin, levofloxacin, moxifloxacin, ofloxacin, fosfomycin, para-aminosalicylate, tetrasodium denofosol, lancovirtide, ribavirin, zanamivir, laminavir, rubisvir, pentamidine, amphotericin B, posaconazole, isavuconazole, caproxine, micafungin, anidulafungin, iloprost, levothyroxine, their salts, solvates, hydrates, polymorphs and esters thereof, combinations, analogs and derivatives thereof.

[0054] In another embodiment, the active agent is a macromolecule, such as a peptide, protein, antibody, antibody fragment, nanobody, nucleic acid.

[0055] Preferably, according to the present invention, the macromolecule is insulin, proinsulin, synthetic insulin, semi-synthetic insulin, bevacizumab, pembrolizumab, atezolizumab, nivolumab, ipilimumab, toll-like receptor agonist, growth hormone releasing peptide, IgG monoclonal antibody, small interfering ribonucleic acid (siRNA), dornase alfa, cyclosporine A, alpha-1 antitrypsin, interleukin antagonist, interferon-α, interferon-β, interferon-γ, interferon-ω, interleukin-2, anti-IgE mAb, catalase, calcitonin, parathyroid hormone, human growth hormone, insulin-like growth factor-I, heparin, rhG-CSF, GM-CSF, Epo-Fc, FSH-Fc, sFc-γRIIb, mRNA,

[0056] In another preferred embodiment, the active agent is an anti-tumor agent, such as for lung cancer and lung tumors.

[0057] Lung cancer is the most common cancer in the world in terms of morbidity and mortality. In most cases, lung cancer is diagnosed at an advanced stage. Therefore, patients often already have metastases in the lungs or other organs, known as extrapulmonary metastases. Treatment modalities are mainly combined, including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy.

[0058] Chemotherapy is used in up to 60% of lung cancer patients, mainly in the advanced stages of the disease. Chemotherapy is currently administered by intravenous injection or infusion or orally, i.e., a systemic route of administration, i.e., systemic chemotherapy. Chemotherapy causes severe systemic toxicity due to (i) the widespread distribution of chemotherapeutic agents in the organism and (ii) the lack of selectivity for cancer cells. Therefore, new more effective and better tolerated treatments are in great need of oncologists.

[0059] Chemotherapy is actually about finding the highest amount of anti-tumor agent to be administered by minimizing the irreversible toxic and adverse side effects of chemotherapy.

[0060] Therefore, very complex treatment regimens are foreseen, which combine very different therapeutic treatments and actions (such as surgery) with a first cycle of radiation therapy, followed by complex cycles of injections or intravenous infusions of anti-tumor agents, which can be the same or different for each cycle and reduced or adjusted according to the side effects identified in the patient's body.

[0061] Every anti-tumor agent or molecule has dose limiting toxicities (DLTs), such as nephrotoxicity, neurotoxicity, etc., which require the introduction of rest periods in the treatment regimen, when irreversible, to allow the patient's body to recover from the adverse side effects.

[0062] In addition, antitumor agents have a half-life, which is generally referred to as their half-life. Half-life is the time required for the concentration or amount of the drug in the body to be reduced by half. The half-life of an antitumor agent is typically between 12 hours and 36 hours, which can be short because it represents the exposure time of the human body to the beneficial effects of the antitumor agent.

[0063] However, due to the dose-limiting toxicity (DLT) of the antitumor agent, the amount of the administered dose during several administrations is still limited and, as mentioned above, should be separated from each other by rest periods or drug holidays.

[0064] The combination of half-life and dose-limiting toxicity, and the fact that antineoplastic agents are administered orally or by injection or intravenous infusion, results in low concentrations of antineoplastic agents that effectively reach the site of solid tumors, limited effects on the tumor itself and high systemic toxicity to the patient's body.

[0065] Another limitation of antineoplastic agents is the cumulative dose, which is the total dose resulting from repeated exposure to the antineoplastic agent in the same part of the body or throughout the body.

[0066] For cisplatin administered by the intravenous route, the cumulative dose is 300 mg / m2 over 4 to 6 cycles. 2 .

[0067] These considerations prompted the present investigators to develop more targeted therapies and on-site injection / infusion.

[0068] Inhalation therapy is of different types and inhalers in the form of nebulizers can be distinguished as different ways of delivering the API to the respiratory tract. Inhalers can also be of different types, dry powder inhalers (DPIs) being one of them.

[0069] Compared to nebulizers, dry powder inhalers (DPIs) are well suited for chemotherapy. They allow administration of high doses of APIs, but also allow administration of poorly water-soluble compounds (i.e., most chemotherapeutic agents in cancer). In addition, DPIs limit environmental contamination with aerosols due to (i) their initiation and actuation solely by the patient's inspiratory flow, and (ii) negligible exhaled drug doses. Finally, DPIs can be designed as single-use devices.

[0070] Therefore, there is a need to develop pulmonary routes for anti-neoplastic agents and adapt current inhalation devices and formulations used in clinical trials to deliver effective anti-cancer therapies to the tumor-bearing lung.

[0071] Prolonging the retention profile of antineoplastic agents in the lung and ensuring that absorption is not too rapid has many advantages. However, achieving a prolonged release profile remains challenging at present because the absorptive surface area of ​​the lung is high, resulting in rapid systemic absorption of the agent.

[0072] As mentioned above, controlled-release DPI formulations based on cisplatin are developed to have high drug loading and high fine particle fractions, with controlled release and extended lung retention, resulting in low systemic distribution. (Levet et al., Int J Pharm [International Journal of Pharmacy] 2017). According to the document, in a lung cancer mouse model, this approach resulted in an in vivo tumor response comparable to a half-dose intravenous regimen (1.0 mg / kg and 0.5 mg / kg, respectively). The intravenous regimen gave good results for extrapulmonary metastasis, while inhaled cisplatin seemed to be more active against lung tumors.

[0073] DPI formulations consisting of paclitaxel-based nanocarriers have also been developed that have increased residence time in the lungs, limited systemic distribution, and are specifically targeted to lung cancer cells by targeting the folate receptor (FR) (Rosière et al., Int JPharm [International Journal of Pharmacy] 2016; Rosière et al., Mol Pharm [Molecular Pharmacy], 2018). FRs, especially FR-α, are overexpressed on the surface of cancer cells in many lung tumors (i.e., more than 70% of adenocarcinomas) and are promising membrane receptors for targeting lung cancer. In a mouse model of lung cancer, compared with intravenous administration alone, FR-α was significantly higher in lung cancer cells than in lung cancer cells. Compared with intravenous Significantly longer survival was observed with inhaled treatment of the FR-targeted drug combined with paclitaxel (the commercial form of paclitaxel).

[0074] To resume, although the use of DPI chemotherapy has led to encouraging preclinical results in terms of pharmacokinetic profile and safety, their efficacy remains rather limited.

[0075] Despite the many advantages that can be gained by achieving a prolonged release profile of an antineoplastic agent, this challenge is even more exacerbated in the context of inhaled chemotherapy because the lungs present a remarkably large absorptive surface, resulting in rapid absorption and availability of the API to the systemic circulation.

[0076] Furthermore, since the lungs have strong defense mechanisms, the elimination of APIs in inhaled therapy is quite rapid due to the efficient clearance mechanisms in the lungs against foreign deposited particles.

[0077] Sebti et al. (Sebti et al. Eur J Pharm Biopharm 2006a; Sebti et al., Eur J Pharm Biopharm 2006b) developed solid lipid macroparticles with budesonide and a lipid matrix consisting of cholesterol, but did not observe any delay in the release profile of budesonide.

[0078] To this end, Depreter et Amighi (Depreter and Amighi, Eur J Pharm Biopharm 2010) developed insulin microparticles coated with a lipid matrix consisting of cholesterol, for which only a slight delay in insulin release was observed.

[0079] To this end, as previously mentioned, Levet et al. have endeavored to prolong the retention time in the lungs, thereby increasing the efficiency of inhaled chemotherapy and identified a lipid matrix composed of tristearin and TPGS as a promising candidate.

[0080] Furthermore, even though lipid-derived excipients for matrix formation are superior to polymers, only a few substances capable of forming lipid matrices are allowed and accepted for use in pharmaceutical compositions to be inhaled due to toxicity reasons compared to other therapeutic treatment routes (Pilcer and Amighi, Int J Pharm 2010).

[0081] Unfortunately, although tristearin based matrices are considered promising, their availability on the market as pharmaceutical compounds is rather limited, whereas the availability of the at least one triglyceride selected from the group comprising monohydroxystearin, dihydroxystearin, trihydroxystearin and mixtures thereof is to a much greater extent.

[0082] Furthermore, tristearin-based matrices were not promising for controlling the release profile of voriconazole, whereas the preparation method (ie, spray drying) and excipient composition were similar to those described by Levet et al. for cisplatin.

[0083] Furthermore, it has been determined according to the invention that the at least one triglyceride selected from the restricted group according to the invention, in addition to obtaining a sustained release profile and prolonged retention of the chemotherapy in the lungs, allows a significant increase in the lung deposition rate relative to the closest triglyceride, tristearin.

[0084] Preferably, the anti-tumor agent is cisplatin, carboplatin, oxaliplatin, docetaxel, paclitaxel, pemetrexed, etoposide, or vinorelbine.

[0085] Further embodiments of the dry powder inhalation formulation according to the invention are mentioned in the appended claims.

[0086] The present invention relates to a method for preparing a dry powder inhalation formulation according to the present invention, comprising the following steps:

[0087] a) mixing the one or more APIs with a predetermined amount of at least one triglyceride selected from the group consisting of monohydroxystearin, dihydroxystearin, trihydroxystearin and mixtures thereof, with or without a solvent,

[0088] b) Bottom-up or top-down methods produce inhalable particles from the aforementioned mixture, such as a micronization step, such as spray drying of a suspension or solution, spray congealing of a solution of the active drug or API in said at least one triglyceride or extrusion, followed by jet milling of a physical mixture of the API and said at least one triglyceride.

[0089] For example, the present invention relates to a method for preparing a dry powder inhalation formulation according to the present invention, comprising the steps of suspending or dissolving a powder of one or more APIs in a predetermined amount of at least one triglyceride to form a particle suspension or solution of one or more APIs (e.g., by melting and / or by extrusion), wherein the triglyceride is selected from the group comprising monohydroxystearin, dihydroxystearin, trihydroxystearin and mixtures thereof, and then reducing the size of the particles of the solution or suspension of one or more APIs obtained after cooling (e.g., by spray-congealing) or extrusion at high speed and / or high pressure to obtain the dry powder inhalation formulation (e.g., by jet milling).

[0090] In another embodiment, the manufacturing method includes the following steps:

[0091] a) homogeneously mixing at least one API with at least one triglyceride to form a homogeneous mixture,

[0092] b) extruding the homogeneous mixture using a (twin-screw) extruder at a suitable temperature to obtain a homogeneous lipid matrix containing the API,

[0093] c) cutting the extrudate to obtain coarse granules / cylinders,

[0094] d) optionally, converting the triglycerides into a stable polymorphic form by storing the coarse granules / cylinders under appropriate storage conditions, and

[0095] e) grinding the granules by using a suitable grinder to obtain fine particles for inhalation (DPI) containing the API and the at least one triglyceride.

[0096] In another aspect, the present invention relates to a process for preparing a dry powder inhalation formulation according to the present invention, comprising the following steps:

[0097] a) suspending or dissolving one or more API powders in a solvent to form a particle suspension or solution of one or more APIs

[0098] b) reducing the size of the particles of the one or more APIs, optionally under high speed and / or high pressure homogenization with cooling to form a suspension of size-reduced particles of the one or more APIs,

[0099] c) mixing a predetermined amount of at least one triglyceride selected from the group consisting of monohydroxystearin, dihydroxystearin, trihydroxystearin and mixtures thereof in a solvent with the microcrystalline suspension or solution to obtain a mixture of the at least one API and the at least one triglyceride

[0100] d) spray drying the mixture of the at least one API and the at least one triglyceride to obtain the dry powder inhalation formulation.

[0101] In a preferred embodiment of the method according to the present invention, the high speed for size reduction is 10000-30000 rpm, preferably 15000-26000 rpm, and the application time is 8-15 minutes, preferably 9-12 minutes.

[0102] Preferably, according to the present invention, the high pressure used in the homogenization step is gradually increased from a first pressure of 2000-10000 psi, preferably 4000-6000 psi, through a predetermined number of pre-grinding cycles of 8-12, preferably 9-11, to a second pressure of 8000-12000 psi, preferably 9000-11000 psi, through a predetermined number of pre-grinding cycles of 8-12, preferably 9-11, and gradually increased to a third pressure of 18000-24000 psi, preferably 19000-22000 psi, through a predetermined number of pre-grinding cycles of 18-22, preferably 19-21.

[0103] In a particularly preferred embodiment according to the present invention, the crystallites of the microcrystalline suspension have a geometric particle size distribution (PSD) d less than or equal to 30 μm, preferably less than 15 μm, preferably less than or equal to 10 μm, preferably less than or equal to 5 μm. 50 .

[0104] In another particularly preferred embodiment according to the present invention, the crystallites of the microcrystalline suspension have a geometric particle size distribution (PSD) d less than or equal to 60 μm, preferably less than or equal to 30 μm, more preferably less than or equal to 15 μm, preferably less than or equal to 10 μm and more preferably less than or equal to 7 μm. 90 .

[0105] In another particularly preferred embodiment according to the present invention, the crystallites of the crystallite suspension have a volume average diameter D[4,3] of less than or equal to 40 μm, preferably less than or equal to 20 μm, more preferably less than or equal to 15 μm, preferably less than or equal to 10 μm, preferably less than or equal to 6 μm.

[0106] In an advantageous preferred embodiment according to the present invention, a pegylated excipient or other excipients are further added.

[0107] Further embodiments of the method according to the invention are mentioned in the appended claims.

[0108] The present invention also relates to the use of dry powder inhalation formulations in pulmonary treatment.

[0109] Preferably, the use according to the invention is foreseen for the treatment of local lung diseases: asthma, COPD, lung infections (eg cystic fibrosis patients, aspergillosis, tuberculosis, etc.) or systemic diseases (eg diabetes, pain, etc.).

[0110] In a variant according to the invention, the dry powder inhalation chemotherapy formulation is used in a multitherapy for the treatment of lung cancer, such as any lung tumor, such as lung metastasis, such as osteosarcoma metastasis, small cell lung cancer or non-small cell lung cancer.

[0111] Advantageously, the multitherapy comprises a primary therapy selected from the group consisting of: intravenous or infusion chemotherapy, immunotherapy, tumor ablative surgery, ablative surgery for resection of part or all of a tumor-bearing organ, curative surgery, radiation therapy, and combinations thereof, and one or more chemotherapies by inhalation as additional therapies.

[0112] The invention also relates to a corresponding treatment method. DETAILED DESCRIPTION

[0113] Other characteristics and advantages of the invention will emerge from the following non-limiting description with reference to the examples and the accompanying drawings.

[0114] In the accompanying drawings, Figure 1 The FPF values ​​(%) of the comparative example (Composition F5 in Levet et al.) and Examples 1 and 2 are shown (mean ± SD, n = 2-3).

[0115] Figure 2 Shown are the release profiles of cisplatin from the inhalable fraction of DPI formulations prepared according to Examples 1 and 2 compared to a comparative formulation consisting of cisplatin microparticles alone.

[0116] Figure 3 The FPF values ​​of Example 10 are shown compared to a comparative formulation consisting of pemetrexed microparticles alone (mean ± SD, n = 3 and 1, respectively), indicating that Example 10 is superior to conventional DPI formulations in terms of lung deposition.

[0117] Figure 4 Shown is the release profile of pemetrexed from the inhalable fraction of the DPI formulation prepared according to Example 10 compared to a comparative formulation consisting of pemetrexed microparticles alone (mean ± SD, n = 3).

[0118] Figure 5The FPF values ​​(mean ± SD) for Example 13 are shown, demonstrating the high lung deposition rate of the insulin-based DPI compositions disclosed herein.

[0119] Figure 6 Shown is the release profile of insulin from the inhalable portion of a DPI formulation prepared according to Example 13 (up to 240 min, mean ± SD, n = 2) (A) compared to a comparative formulation described by Depreter et al. (up to 180 min) (B).

[0120] Figure 7 Shown is the release profile of cisplatin from the inhalable fraction of the DPI formulation prepared according to Example 16 compared to a comparative formulation consisting of cisplatin microparticles (mean ± SD, n = 3).

[0121] Figure 8 The FPF values ​​of Examples 19 and 20 are shown compared with Comparative Examples BUD-TS4 and BUD-TS5 (mean ± SD, n = 3). (***) p < 0.001, t-test, indicating that the budesonide composition disclosed in the present invention is superior to other triglyceride-based budesonide DPI formulations in terms of lung deposition.

[0122] Fig. 9 The release profiles of budesonide from the inhalable fraction of the micronized budesonide comparative example and the DPI formulations prepared according to Examples 19, 20 and 21 are shown (n=1), demonstrating the controlled release profile of budesonide from the composition of the present invention and the possibility of adjusting the release profile by adjusting the drug / lipid ratio.

[0123] Example.-

[0124] Example 1.-Preparation of Cisplatin Dry Powder Formulation for Inhalation n°1

[0125] Briefly, crude cisplatin microcrystals obtained from bulk powder (Shanghai Jinhe Bio-technology Co., Ltd., Shanghai, PRC) were first suspended in 50 mL of isopropanol to a concentration of 5% w / v and were homogenized at high speed (10 min, 24000 rpm) (X620 motor and T10 dispersion shaft, Ingenieurbüro CAT M. Zipperer GmbH, Staufen, Germany) and high pressure homogenization (EmulsiFlex-C5 high pressure homogenizer, Avestin Inc., Ottawa, Canada) at 5000 psi, then at 10000 psi, each through 10 pre-grinding cycles, then at 20000 psi, through 20 grinding cycles to reduce the size. A heat exchanger was connected to the homogenization valve and maintained at -15 °C using a F32-MA cooling circulator (ulabo GmbH, Seelbach, Germany). At the end of the process an aliquot was taken from the suspension to measure the particle size distribution (PSD) of the cisplatin microcrystals by laser diffraction (see below).

[0126] Then, hydrogenated castor oil (BASF, Ludwigshafen, Germany) and TPGS (Sigma-Aldrich, St. Louis, USA) dissolved in heated isopropanol were added to the microcrystalline suspension to obtain a final concentration of 1.32% w / v cisplatin and 0.68% w / v hydrogenated castor oil / TPGS (99:1 w / w) mixture and spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain the DPI formulation for human use.

[0127] The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70 °C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0128] The geometric PSD of bulk cisplatin (cisplatin microparticles and cisplatin dry powder formulations from the size reduction process) is measured as suspended and individualized particles. The Mastersizer 3000 laser diffractometer (Malvern Instruments Ltd., Worcestershire, UK) connected to a Hydro MV dispenser (Malvern Instruments Ltd.) equipped with a 40W ultrasonic probe is used. Bulk cisplatin and aliquots from the size reduction process are measured in isopropanol saturated with cisplatin. The cisplatin dry powder formulation is pre-dispersed, vortexed and measured in a 0.9% aqueous solution of NaCl saturated with 0.1% w / v poloxamer 407 (BASF, Ludwigshafen, Germany) saturated with cisplatin. PSD is expressed as volume median diameter d (0.5) (wherein 50% of the particles are located below the diameter represented), volume average diameter D [4,3] and the percentage of fine particles determined by the cumulative undersize curve (% of particles below 5 μm). The PSD results were within the range expected according to the present invention.

[0129] Example 2.-Preparation of Cisplatin Dry Powder Formulation for Inhalation n°2

[0130] Briefly, crude cisplatin microcrystals obtained from bulk powder (Shanghai Jinhe Bio-technology Co., Ltd., Shanghai, PRC) were first suspended in 50 mL of isopropanol to a concentration of 5% w / v and were homogenized at high speed (10 min, 24000 rpm) (X620 motor and T10 dispersion shaft, Ingenieurbüro CAT M. Zipperer GmbH, Staufen, Germany) and high pressure homogenization (EmulsiFlex-C5 high pressure homogenizer, Avestin Inc., Ottawa, Canada) at 5000 psi, then at 10000 psi, each through 10 pre-grinding cycles, then at 20000 psi, through 20 grinding cycles to reduce the size. A heat exchanger was connected to the homogenization valve and maintained at -15 °C using a F32-MA cooling circulator (ulabo GmbH, Seelbach, Germany). At the end of the process an aliquot was taken from the suspension to measure the particle size distribution (PSD) of the cisplatin microcrystals by laser diffraction (see below).

[0131] Then, hydrogenated castor oil (BASF, Ludwigshafen, Germany) and TPGS (Sigma-Aldrich, St. Louis, USA) dissolved in heated isopropanol were added to the microcrystalline suspension to obtain a final concentration of 1.0% w / v cisplatin and 1.0% w / v hydrogenated castor oil / TPGS (99:1 w / w) mixture and spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0132] The geometric PSD of bulk cisplatin (cisplatin microparticles from the size reduction process and cisplatin dry powder formulation) was measured as suspended and individualized particles. It was performed as described in Example 1 using a Mastersizer 3000 laser diffractometer (Malvern Instruments Ltd., Worcestershire, UK) connected to a Hydro MV dispenser (Malvern Instruments Ltd.) equipped with a 40 W ultrasonic probe.

[0133] Example 3.-Deposition rate analysis of cisplatin dry powder formulations prepared according to Examples 1 and 2.

[0134] The fine particle fraction values ​​of the formulations according to the comparative example (composition F5 in Levet et al.) and according to examples 1 and 2 have been analyzed.

[0135] The fine particle fraction (FPF) - which is the percentage of recovered dose of cisplatin-based particles with an aerodynamic diameter (dae) below 5 μm - and the aerodynamic PSD characterized by the mass median aerodynamic diameter (MMAD) were determined using the MsLI (Copley Scientific, Nottingham, UK) - Apparatus C - as described in the European Pharmacopoeia 8.0. (2014). A mass of 20 mg of each DPI formulation (Comparative Example and according to Example 2), previously sieved through a 355 mm stainless steel mesh, was weighed in a size 3 HPMC capsule (Quali-VI, Qualicaps, Madrid, Spain) and deposited in the MsLI using an RS.01 dry powder inhaler (RPCPlastiape, Osnago, Italy), which was mounted on the inhalation port with its adapter (n=3).

[0136] A deposition flow rate of 100 ± 5 L / min measured using a DFM3 flow meter (Copley Scientific, Nottingham, UK) was obtained with two HCP5 air pumps (Copley Scientific, Nottingham, UK) connected in series to a TPK critical flow controller (Copley Scientific, Nottingham, UK).

[0137] At this flow rate, the cut-off diameters between the stages of MsLI were 10.0, 5.3, 2.4, 1.3, and 0.4 mm. The microporous collector (MOC) filter (i.e., stage 5) contained a Fluoropore 9 cm PTFE membrane with a pore size of 0.45 mm bonded to a high-density polyethylene support (Merck Millipore, Darmstadt, Germany). A critical flow controller was used to ensure a critical flow of 2.4 s sedimentation time and P3 / P2 ratio <0.5 at 100 L / min as required by European Pharmacopoeia 8.0. (2014).

[0138] After impact, the first four stages of MsLI were rinsed for the first time using 20 mL pre-filled 0.5% w / v poloxamer 407 in ultrapure water / isopropanol (60:40 v / v) as the diluent phase, rinsed for the second time using 25 mL DMF, and rinsed for the third time using the diluent phase adjusted to 100.0 mL and sonicated for 30 minutes. After dissolution with 100.0 mL of the diluent phase and sonication for 30 minutes, drug deposition in the capsule, in the device, in the inhalation port, and on the MOC filter was determined. The impact mass in each stage was determined by quantifying the cisplatin content using a validated electrothermal atomic absorption spectrometry (ETAAS) method described by Levet et al. (Levet, Int J Pharm 2016).

[0139] The results were then plotted in Copley Inhaler Test Data Analysis Software1 (Copley Scientific, Nottingham, UK) to obtain the FPD below 5 μm. This was done by interpolating the recovered mass with the cut-off diameter of the corresponding stage. The FPF is expressed as a percentage of the nominal dose.

[0140] Figure 1 The FPF values ​​(%) of the comparative example (Composition F5 in Levet et al.) and Examples 1 and 2 are shown (mean ± SD, n = 2-3), indicating that the cisplatin composition disclosed in the present invention is superior to other triglyceride-based cisplatin DPI formulations in terms of lung deposition.

[0141] Example 4.-Dissolution rate analysis of cisplatin from cisplatin dry powder formulations prepared according to Examples 1 and 2.

[0142] The dissolution properties of DPI formulations were established by applying the method described by Levet et al. (Levet et al., Int J Pharm 2016). This method is derived from the paddle-disc method of USP39 using a modified V-type dissolution apparatus for transdermal patches. The release profiles of cisplatin were determined from the total respirable fraction (dae less than or equal to 5 μm) of DPI formulations selected using a rapid screening impactor (FSI, Copley Scientific, Nottingham, UK). An appropriate mass of each DPI formulation equivalent to a deposited dose of 3 mg cisplatin was weighed into a No. 3 HPMC capsule (Quali-VI Qualicaps, Madrid, Spain). It was then deposited on a 0.45 mm pore size using an RS.01 DPI apparatus (RPC Plastiape). The samples were filtered through a hydrophobic PTFE membrane filter (Merck Millipore, Darmstadt, Germany) with an FSI (2.4 s, 100 L / min) equipped with a corresponding pre-separator insert. A 0.4 mm hydrophilic polycarbonate filter (Merck-Milipore, Germany) covered the Fluoropore filter with the deposited powder facing upward and was fixed to a watch glass-PTFE disc assembly (Copley, Nottingham, UK) using the provided clips and PTFE mesh. The disc assembly was then immersed in the dissolution vessel of an AT7 dissolution apparatus (Sotax AG, Aesch, Switzerland) with 400 mL of modified simulated lung fluid (mSLF) (Son and McConville, 2009) - a medium that simulates lung electrolytes and surfactant composition.

[0143] Dissolution testing was achieved at 37 ± 0.2 °C, pH 7.35 ± 0.05 according to the water tank conditions. The rotation speed of the paddle (set to 25 ± 2 mm between the paddle and the center of the disk assembly) was set to 50 ± 4 rpm. A sample volume of 2.0 mL was filtered through a 0.22 mm pore size cellulose acetate syringe filter (VWR, Leuven, Belgium) at a predetermined time between 2 minutes and 24 hours and replaced with 2.0 mL of free preheated mSLF.

[0144] At the end of the dissolution assay, the disk assembly was opened into the dissolution vessel and sonicated for 30 min to establish a 100% cisplatin dissolution value.

[0145] Figure 2 Shown are the release profiles of cisplatin from the inhalable fraction of DPI formulations prepared according to Examples 1 and 2 compared to a comparative formulation consisting of cisplatin microparticles alone.

[0146] Example 5.-Preparation of insulin dry powder formulation n°1

[0147] First, insulin was suspended in isopropanol (2% w / v) and the dispersion of the powder was ensured by ultrasonic treatment in a 40kHz Branson 2510 bath for 10 minutes. Then the particle size was reduced using an EmulsiFlex-C5 high pressure homogenizer (Aves-tin Inc., Ottawa, Canada). First, the insulin suspension was pre-ground and the low-pressure homogenization cycle was further reduced in order to reduce the particle size (10 cycles at 7000PSI and 10 cycles at 12,000PSI). Then, HPH was applied at 24,000PSI for 30 cycles. These cycles were carried out by directly recirculating the treated suspension to the sample tank (closed loop). Because HPH caused the sample temperature to rise (rising by 30°C after 20 cycles at 24,000PSI), all operations were carried out using a heat exchanger placed before the homogenization valve, and the sample temperature was maintained at 5 ± 1°C.

[0148] At the end of the process an aliquot was taken from the suspension to measure the particle size distribution (PSD) of the insulin microcrystals by laser diffraction (see below).

[0149] Then, hydrogenated castor oil (BASF, Ludwigshafen, Germany) and TPGS (Sigma-Aldrich, St. Louis, USA) dissolved in heated isopropanol were added to the microcrystalline suspension to obtain a final concentration of 1.0% w / v insulin and 1.0% w / v hydrogenated castor oil / TPGS (99:1 w / w) mixture and spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0150] The geometric PSD of bulk insulin (insulin microparticles and insulin dry powder formulations from the size reduction process) was measured as suspended and individualized particles and is within the scope of the present invention. As described in Example 1, a Mastersizer 3000 laser diffractometer (Malvern Instruments Ltd., Worcestershire, UK) connected to a Hydro MV dispenser (Malvern Instruments Ltd.) equipped with a 40W ultrasonic probe was used.

[0151] Example 6.-Preparation of insulin dry powder formulation n°2

[0152] First, insulin was suspended in isopropanol (2% w / v) and the dispersion of the powder was ensured by ultrasonic treatment in a 40kHz Branson 2510 bath for 10 minutes. Then the particle size was reduced using an EmulsiFlex-C5 high pressure homogenizer (Aves-tin Inc., Ottawa, Canada). First, the insulin suspension was pre-ground and the low-pressure homogenization cycle was further reduced in order to reduce the particle size (10 cycles at 7000PSI and 10 cycles at 12,000PSI). Then, HPH was applied at 24,000PSI for 30 cycles. These cycles were carried out by directly recirculating the treated suspension to the sample tank (closed loop). Because HPH caused the sample temperature to rise (rising by 30°C after 20 cycles at 24,000PSI), all operations were carried out using a heat exchanger placed before the homogenization valve, and the sample temperature was maintained at 5 ± 1°C.

[0153] At the end of the process an aliquot was taken from the suspension to measure the particle size distribution (PSD) of the insulin microcrystals by laser diffraction (see below).

[0154] Then, hydrogenated castor oil (BASF, Ludwigshafen, Germany) and TPGS (Sigma-Aldrich, St. Louis, USA) dissolved in heated isopropanol were added to the microcrystalline suspension to obtain a final concentration of 1.5% w / v insulin and 0.5% w / v hydrogenated castor oil / TPGS (99:1 w / w) mixture and spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min compressed air and 35 m 3The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0155] The geometric PSD of bulk insulin (insulin microparticles and insulin dry powder formulations from the size reduction process) was measured as suspended and individualized particles and is within the scope of the present invention. As described in Example 1, a Mastersizer 3000 laser diffractometer (Malvern Instruments Ltd., Worcestershire, UK) connected to a Hydro MV dispenser (Malvern Instruments Ltd.) equipped with a 40W ultrasonic probe was used.

[0156] Example 7.-Preparation of budesonide dry powder formulation for inhalation n° 1

[0157] Budesonide (1% w / v) was first dissolved in isopropanol under magnetic stirring. Then, hydrogenated castor oil (BASF, Ludwigshafen, Germany) and TPGS (Sigma-Aldrich, St. Louis, USA) dissolved in heated isopropanol were added to the microcrystalline suspension to obtain a final concentration of 1.0% w / v budesonide and 1.0% w / v hydrogenated castor oil / TPGS (99:1 w / w) mixture and spray dried with Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flavel, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0158] The geometric PSD of the bulk budesonide dry powder formulation was measured as suspended and individualized particles and is within the scope of the present invention. It was performed as described in Example 1 using a Mastersizer 3000 laser diffractometer (Malvern Instruments Ltd., Worcestershire, UK) connected to a Hydro MV dispenser (Malvern Instruments Ltd.) equipped with a 40W ultrasonic probe.

[0159] Example 8.-Preparation of budesonide dry powder formulation for inhalation n°2

[0160] Budesonide (1.5% w / v) was first dissolved in isopropanol under magnetic stirring. Then, hydrogenated castor oil (BASF, Ludwigshafen, Germany) and TPGS (Sigma-Aldrich, St. Louis, USA) dissolved in heated isopropanol were added to the microcrystalline suspension to obtain a final concentration of 1.5% w / v budesonide and 0.5% w / v hydrogenated castor oil / TPGS (99:1 w / w) mixture and spray dried with Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flavel, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0161] The geometric PSD of the bulk budesonide dry powder formulation was measured as suspended and individualized particles and is within the scope of the present invention. It was performed as described in Example 1 using a Mastersizer 3000 laser diffractometer (Malvern Instruments Ltd., Worcestershire, UK) connected to a Hydro MV dispenser (Malvern Instruments Ltd.) equipped with a 40W ultrasonic probe.

[0162] Example 9. Preparation of budesonide dry powder formulation n°3.

[0163] 10 g of micronized budesonide, 9.9 g of hydrogenated castor oil and 0.1 g of TPGS were mixed in Mixer (Willy A. Bachofen AG, Muttenz, Switzerland) is mixed to even. Then at an appropriate temperature, a homogeneous blend is extruded by a twin screw extruder (Process-11, Thermo Fischer Scientific, Massachusetts, USA) to obtain a homogeneous lipid matrix. The extrudate is then cut to obtain coarse particles, and the particles are placed in an incubator under appropriate storage conditions so that the lipid matrix is ​​converted into stable polymorphs. Finally, the particles are ground by a jet mill (with appropriate particle feed rate, injection pressure and grinding pressure) to obtain microparticles (DPI) for the inhalation of the human body.

[0164] Example 10.-Preparation of pemetrexed dry powder formulation for inhalation n°1

[0165] Briefly, crude pemetrexed disodium (heptahydrate form) microcrystals obtained from bulk powder (Carbosynth Limited, Berkshire, UK) were first suspended in 50 mL of isopropanol to a concentration of 1% w / v in the presence of 0.05% w / v TPGS (Sigma-Aldrich, St. Louis, USA), and were reduced in size by high speed (10 min, 24000 rpm) (X620 motor and T10 dispersion shaft, Ingenieurbüro CAT M. Zipperer GmbH, Staufen, Germany) and high pressure homogenization (EmulsiFlex-C3 high pressure homogenizer, Avestin Inc., Ottawa, Canada) at 25000 psi for 20 grinding cycles. A heat exchanger was connected to the homogenization valve and maintained at +5°C using a F32-MA cooling circulator (Julabo GmbH, Seelbach, Germany). At the end of the process an aliquot was taken from the suspension to measure the particle size distribution (PSD) of the pemetrexed microcrystals by laser diffraction (see below).

[0166] Then, 1% w / v hydrogenated castor oil (BASF, Ludwigshafen, Germany) was dissolved in the heated (50°C) microcrystalline suspension and spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0167] The geometric PSD of bulk pemetrexed (pemetrexed microparticles from the size reduction process and pemetrexed dry powder formulation) was measured as suspended and individualized particles and is within the scope of the present invention. It was performed as described in Example 1 using a Mastersizer 3000 laser diffractometer (Malvern Instruments Ltd., Worcestershire, UK) connected to a Hydro MV dispenser (Malvern Instruments Ltd.) equipped with a 40W ultrasonic probe.

[0168] Example 11.- Sedimentation rate analysis of a pemetrexed dry powder formulation prepared according to Example 10.

[0169] The in vitro lung deposition pattern and FPF values ​​of the formulation according to Example 10 were analyzed.

[0170] FPF - which is the percentage of recovered dose related to pemetrexed-based particles with an aerodynamic diameter (dae) below 5 μm - and aerodynamic PSD characterized by MMAD were determined using NGI (Copley Scientific, Nottingham, UK) - Apparatus E - as described in European Pharmacopoeia 8.0. (2014). A mass of 20 mg of each DPI formulation (Example 10 and comparative formulation consisting of pemetrexed microparticles alone), previously sieved through a 355 mm stainless steel mesh, was weighed in a size 3 HPMC capsule (Quali-VI, Qualicaps, Madrid, Spain) and deposited in the NGI using a RS.01 dry powder inhaler (RPC Plastiape, Osnago, Italy), which was mounted on the inhalation port with its adapter (n=3).

[0171] A deposition flow rate of 100 ± 5 L / min measured using a DFM3 flow meter (Copley Scientific, Nottingham, UK) was obtained with two HCP5 air pumps (Copley Scientific, Nottingham, UK) connected in series to a TPK critical flow controller (Copley Scientific, Nottingham, UK).

[0172] At this flow rate, the cut-off diameters between the stages of the NGI were 6.12, 3.42, 2.18, 1.31, 0.72, 0.40 and 0.24 μm. A critical flow controller was used to ensure a settling time of 2.4 s and a critical flow of P3 / P2 ratio < 0.5 at 100 L / min, as required by European Pharmacopoeia 8.0. (2014).

[0173] After impact, ultrapure water / DMF (30:70v / v) was used as the diluent phase to collect the pemetrexed material deposited in the capsule, device, inlet, pre-separator, 7 stages and MOC of NGI, and ultrasonic treatment was performed for 30 minutes. The impact mass in each stage was determined by quantitative pemetrexed content by verified HPLC. The chromatographic system (HP 1200 series, Agilent Technologies, Diegem, Belgium) was equipped with a quaternary pump, an automatic sampler and a diode array detector. Separation was performed on a reversed phase Hypersil Gold C18 column (5mm, 250mm x 4.6mm) (Thermo Fisher Scientific, Waltham, USA). The mobile phase was composed of ultrapure water / acetonitrile (86:14) acidified with 0.4% formic acid, delivered at a flow rate of 1mL / min. Quantification was performed at 256nm. The injection volume was 20 μL, the temperature was set at 30 °C, and the analytical run time was 15 min.

[0174] The results were then plotted in Copley Inhaler Test Data Analysis Software1 (Copley Scientific, Nottingham, UK) to obtain the FPD below 5 μm. This was done by interpolating the recovered mass with the cut-off diameter of the corresponding stage. The FPF is expressed as a percentage of the nominal dose.

[0175] Figure 3 The FPF values ​​of Example 10 are shown compared to a comparative formulation consisting of pemetrexed microparticles alone (mean ± SD, n = 3 and 1, respectively), indicating that Example 10 is superior to conventional DPI formulations in terms of lung deposition.

[0176] Example 12 .- Analysis of the dissolution rate of pemetrexed from a pemetrexed dry powder formulation prepared according to Example 10.

[0177] The dissolution properties of DPI formulations were established by applying a modification of the method described by Pilcer et al. (Pilcer et al., J Pharm Sci [Journal of Pharmaceutical Science] 2013). A dissolution system (Copley Scientific, Nottingham, UK) developed specifically for DPI release profile studies was used, and its method was adapted from the "paddle disk method" (Eur.Ph.7). In order to study the release profile of particles deposited in the lungs, the pemetrexed formulation was first graded with NGI. The cup of stage 3 was selected to be equipped with a removable disk insert to collect particles. Of particular interest is that at a selected inhalation rate (100 L / min, 2.4 s), the cutoff diameter of stage 3 was 2.18-3.42 μm, allowing the selection of particles targeting the lungs. Capsules with an appropriate amount of the formulation according to Example 10 were weighed to collect about 6 mg of pemetrexed in stage 3. The disk inserts were then covered with a polycarbonate membrane (0.4 μm pore size) (Merck Millipore) and placed in a paddle dissolution apparatus (Erweka DT6; ERWEKA GmbH, Heusenstamm, Hesse, Germany) filled with 400 mL of mSLF (Son and McConville, 2009) - a medium that simulates lung electrolyte and surfactant composition.

[0178] Dissolution testing was achieved at 37 ± 0.2 °C, pH 7.35 ± 0.05 according to the water tank conditions. The rotation speed of the paddle (set to 25 ± 2 mm between the paddle and the center of the disk assembly) was set to 50 ± 4 rpm. A sample volume of 2.0 mL was filtered through a 0.22 mm pore size cellulose acetate syringe filter (VWR, Leuven, Belgium) at a predetermined time between 2 minutes and 24 hours and replaced with 2.0 mL of free preheated mSLF.

[0179] At the end of the dissolution assay, the disk assembly was opened into the dissolution vessel and sonicated for 30 minutes to establish the 100% pemetrexed dissolution value.

[0180] Figure 4 Shown is the release profile of pemetrexed from the inhalable fraction of the DPI formulation prepared according to Example 10 compared to a comparative formulation consisting of pemetrexed microparticles alone (mean ± SD, n = 3).

[0181] The similarity factor f2 was used to compare the two dissolution profiles (Shah et al., Pharm Res 1998). The profiles were significantly different (f2 < 50). In addition, the cumulative release values ​​of Example 10 at all time points were significantly lower than those of pemetrexed microcrystals (p < 0.05, t-test), for example, at 1 hour, 53 ± 9% and 97.9 ± 0.9%, respectively (p < 0.01), indicating a controlled release profile of pemetrexed from the composition of the present invention.

[0182] Example 13.-Preparation of insulin dry powder formulation n°3

[0183] First, magnetic stirring is used to suspend insulin (Sigma-Aldrich) in isopropanol (1% w / v), and the dispersion of the powder is ensured by ultrasonic treatment in a 40kHz Branson 2510 bath for 10 minutes. Then an EmulsiFlex-C3 high pressure homogenizer (Aves-tin Inc., Ottawa, Canada) is used to reduce the particle size by 30 cycles at 22,000PSI. These cycles are carried out by directly recirculating the treated suspension into the sample tank (closed loop). Because HPH causes the sample temperature to rise, all operations are carried out using a heat exchanger placed before the homogenizing valve, and the sample temperature remains at 5 ± 1°C.

[0184] At the end of the process an aliquot was taken from the suspension to measure the particle size distribution (PSD) of the insulin microcrystals by laser diffraction (see below).

[0185] Then, 1% w / v hydrogenated castor oil (BASF, Ludwigshafen, Germany) was dissolved in the heated (50°C) microcrystalline suspension and spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0186] The geometric PSD of bulk insulin (insulin microparticles and insulin dry powder formulations from the size reduction process) was measured as suspended and individualized particles and is within the scope of the present invention. As described in Example 1, a Mastersizer 3000 laser diffractometer (Malvern Instruments Ltd., Worcestershire, UK) connected to a Hydro MV dispenser (Malvern Instruments Ltd.) equipped with a 40W ultrasonic probe was used.

[0187] Example 14.- Sedimentation rate analysis of an insulin dry powder formulation prepared according to Example 13.

[0188] The FPF value of the formulation according to Example 13 has been analyzed.

[0189] The FPF is determined using a fast screening impactor (FSI) (Copley Scientific, Nottingham, UK) - a percentage of the recovered dose of insulin-based particles with a dae lower than 5 μm. The FSI uses a two-stage separation process in which the first large non-inhalable agglomerates are captured in a liquid trap, followed by a fine cutting impact stage of 5 microns (i.e. corresponding to the FPF). A DPI formulation (according to Example 13) of 10 mg pre-screened through a 355 mm stainless steel mesh was weighed in a No. 3 HPMC capsule (Quali-VI, Qualicaps, Madrid, Spain) and deposited in the FSI using an RS.01 dry powder inhaler (RPCPlastiape, Osnago, Italy), which was mounted on the inhalation port with its adapter (n=3).

[0190] A deposition flow rate of 100 ± 5 L / min measured using a DFM3 flow meter (Copley Scientific, Nottingham, UK) was obtained with two HCP5 air pumps (Copley Scientific, Nottingham, UK) connected in series to a TPK critical flow controller (Copley Scientific, Nottingham, UK). The critical flow controller was used to ensure a deposition time of 2.4 s at 100 L / min.

[0191] After impact, the insulin material deposited on the capsule, device, inlet, pre-separator and on the Fluoropore 9cm PTFE membrane with a pore size of 0.45mm bonded to a high-density polyethylene carrier (Merck Millipore, Darmstadt, Germany) was collected with 0.01M HCl as the dilution phase and ultrasonicated for 30 minutes. The impact mass in each stage was determined by quantitative insulin content using the HPLC method described in European Pharmacopoeia 9.2. (2017). FPF is expressed as a percentage of the nominal dose.

[0192] Figure 5 The FPF values ​​(mean ± SD) for Example 13 are shown, demonstrating the high lung deposition rate of the insulin-based DPI compositions disclosed herein.

[0193] Example 15.- Analysis of the dissolution rate of insulin from a dry powder formulation of insulin prepared according to Example 13.

[0194] The dissolution properties of the DPI formulation according to Example 13 are established by applying the modification of the method described by Depreter et al. (Depreter et al., Eur J Pharm Biopharm [European Journal of Pharmacy and Biopharmaceutics] 2012). Use a dissolution system (Copley Scientific, Nottingham, UK) developed specifically for DPI release curve research, and its method is adapted from the "paddle disc method" (Eur.Ph.7). In order to study the release curve of particles deposited in the lungs, the classification of insulin formulations is first carried out with NGI. The cup of the 3rd stage is selected to be equipped with a removable disc plug-in to collect particles. Of particular interest is that under a selected inhalation rate (100L / min, 2.4s), the cut-off diameter of the 3rd stage is 2.18-3.42 μm, allowing the selection of particles targeting the lungs. Capsules with an appropriate amount of the formulation according to Example 13 are weighed to collect about 3 mg of insulin in the 3rd stage. The disk insert was then covered with a polycarbonate membrane (0.4 μm pore size) (Merck Millipore) and placed in a paddle dissolution apparatus (Erweka DT6; ERWEKA GmbH, Heusenstamm, Hesse, Germany) filled with 400 mL 0.01 mM phosphate buffer (PBS) pH 7.4.

[0195] Dissolution testing was performed at 37 ± 0.2 °C, pH 7.35 ± 0.05 according to the water tank conditions. The speed of the paddle (set to 25 ± 2 mm between the paddle and the center of the disk assembly) was set to 50 ± 4 rpm. A volume of 5.0 mL was sampled at a predetermined time between 2 minutes and 24 hours and replaced with 5.0 mL of free preheated PBS.

[0196] At the end of the dissolution assay, the disk assembly was opened into the dissolution vessel and sonicated for 30 minutes to establish a 100% insulin dissolution value.

[0197] The samples were lyophilized in the presence of 3% w / v trehalose (Christ Epsilon 1-6). The lyophilizate was dissolved in 500 μL HCl 0.02 N and injected into the HPLC system using the method described in European Pharmacopoeia 9.2. (2017).

[0198] Figure 6Shown is the release profile of insulin from the inhalable portion of a DPI formulation prepared according to Example 13 (up to 240 min, mean ± SD, n = 2) (A) compared to a comparative formulation described by Depreter et al. (up to 180 min) (B).

[0199] The cumulative release values ​​of Example 13 at different time points were lower than those of the two formulations of Depreter et al., for example, at 1 hour, they were about 60% and about 100%, respectively, which indicates that the insulin composition disclosed in the present invention is superior to the insulin microcrystals and lipid-coated insulin microcrystals described by Depreter et al. in controlling insulin release (respectively 100% and 100%, respectively). Figure 6 F1 and F2 in ).

[0200] Example 16.-Preparation of Cisplatin Dry Powder Formulation n°3 and Comparative Example

[0201] First, cisplatin (Umicore, Hanau-Wolfgang, Germany) is suspended in 50mL ethanol to reach a concentration of 5% w / v, and EmulsiFlex-C3 high pressure homogenizer (Avestin Inc., Ottawa, Canada) is used by high speed (10 minutes, 24000rpm) (X620 motor and T10 dispersion shaft, Ingenieurbüro CAT M.Zipperer GmbH, Staufen, Germany) and high pressure homogenization, with 20,000PSI, through 40 cycles to reduce the size. These cycles are carried out by directly recycling the treated suspension into the sample tank (closed loop). Because HPH causes the sample temperature to rise, all operations are carried out using the heat exchanger placed before the homogenization valve, and the sample temperature is maintained at 15 ± 1 ° C.

[0202] At the end of the process an aliquot was taken from the suspension to measure the PSD of the cisplatin microcrystals by laser diffraction (see below).

[0203] Then, hydrogenated castor oil (BASF, Ludwigshafen, Germany) and TPGS (Sigma-Aldrich, St. Louis, USA) (or tristearin for comparative examples) dissolved in heated isopropanol were added to the microcrystalline suspension to give a final concentration of 2.0% w / v cisplatin and 2.0% w / v triglyceride / TPGS (99:1 w / w) mixture and spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to give a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0204] The geometric PSD of bulk cisplatin (cisplatin microparticles from the size reduction process and cisplatin dry powder formulation) was measured as suspended and individualized particles and is within the scope of the present invention. It was performed as described in Example 1 using a Mastersizer 3000 laser diffractometer (Malvern Instruments Ltd., Worcestershire, UK) connected to a Hydro MV dispenser (Malvern Instruments Ltd.) equipped with a 40W ultrasonic probe.

[0205] Example 17.-Based on Example 6 Deposition rate analysis of cisplatin dry powder formulation prepared by 16.

[0206] The in vitro lung deposition pattern and FPF values ​​of the formulation according to Example 16 were analyzed.

[0207] The FPF - which is the percentage of recovered dose related to cisplatin-based particles with a dae below 5 μm - and the aerodynamic PSD characterized by MMAD were determined using the NGI (Copley Scientific, Nottingham, UK) - Apparatus E - as described in the European Pharmacopoeia 8.0. (2014). A mass of 20 mg of the DPI formulation (according to Example 17), previously sieved through a 355 mm stainless steel mesh, was weighed in a size 3 HPMC capsule (Quali-VI, Qualicaps, Madrid, Spain) and deposited in the NGI using a RS.01 dry powder inhaler (RPC Plastiape, Osnago, Italy), which was mounted on the inhalation port with its adapter (n=3).

[0208] A deposition flow rate of 100 ± 5 L / min measured using a DFM3 flow meter (Copley Scientific, Nottingham, UK) was obtained with two HCP5 air pumps (Copley Scientific, Nottingham, UK) connected in series to a TPK critical flow controller (Copley Scientific, Nottingham, UK).

[0209] At this flow rate, the cut-off diameters between the stages of the NGI were 6.12, 3.42, 2.18, 1.31, 0.72, 0.40 and 0.24 μm. A critical flow controller was used to ensure a settling time of 2.4 s and a critical flow of P3 / P2 ratio < 0.5 at 100 L / min, as required by European Pharmacopoeia 8.0. (2014).

[0210] After impact, the cisplatin material deposited in the capsule, device, inlet, pre-separator, 7 stages and MOC of NGI was collected with DMF as diluent phase and sonicated for 30 minutes. The impact mass in each stage was determined by quantifying the cisplatin content by the validated ETAAS method described by Levet et al. (Levet, Int JPharm [International Journal of Pharmacy] 2016).

[0211] The results were then plotted in Copley Inhaler Test Data Analysis Software1 (Copley Scientific, Nottingham, UK) to obtain the FPD below 5 μm. This was done by interpolating the recovered mass with the cut-off diameter of the corresponding stage. The FPF is expressed as a percentage of the nominal dose.

[0212] The results obtained, combined with those obtained in Example 3, indicate that the cisplatin compositions disclosed herein are superior to other triglyceride-based cisplatin DPI formulations in terms of lung deposition.

[0213] Example 18.-Dissolution rate analysis of cisplatin from a cisplatin dry powder formulation prepared according to Example 16.

[0214] The dissolution properties of the DPI formulations were established by applying a modification of the method described by Pilcer et al. (Pilcer et al., J Pharm Sci [Journal of Pharmaceutical Science] 2013). A dissolution system (Copley Scientific, Nottingham, UK) developed specifically for DPI release profile studies was used, and its method was adapted from the "paddle disk method" (Eur.Ph.7). In order to study the release profile of particles deposited in the lungs, the cisplatin formulation was first graded with NGI. The cup of stage 3 was selected to be equipped with a removable disk insert to collect particles. Of particular interest is that at a selected inhalation rate (100 L / min, 2.4 s), the cutoff diameter of stage 3 was 2.18-3.42 μm, allowing the selection of particles targeting the lungs from a capsule filled with an appropriate amount of the formulation according to Example 16 to deposit about 2 mg of cisplatin on stage 3. The disk inserts were then covered with a polycarbonate membrane (0.4 μm pore size) (Merck Millipore) and placed in a paddle dissolution apparatus (Erweka DT6; ERWEKA GmbH, Heusenstamm, Hesse, Germany) filled with 400 mL of mSLF (Son and McConville, 2009) - a medium that simulates lung electrolyte and surfactant composition.

[0215] Dissolution testing was achieved at 37 ± 0.2 °C, pH 7.35 ± 0.05 according to the water tank conditions. The rotation speed of the paddle (set to 25 ± 2 mm between the paddle and the center of the disk assembly) was set to 50 ± 4 rpm. A sample volume of 2.0 mL was filtered through a 0.22 mm pore size cellulose acetate syringe filter (VWR, Leuven, Belgium) at a predetermined time between 2 minutes and 24 hours and replaced with 2.0 mL of free preheated mSLF.

[0216] At the end of the dissolution assay, the disk assembly was opened into the dissolution vessel and sonicated for 30 min to establish a 100% cisplatin dissolution value.

[0217] Figure 7 Shown is the release profile of cisplatin from the inhalable fraction of the DPI formulation prepared according to Example 16 compared to a comparative formulation consisting of cisplatin microparticles (mean ± SD, n = 3).

[0218] The similarity factor f2 was used to compare the two dissolution profiles (Shah et al., Pharm Res 1998). The profiles were significantly different (f2 < 50). In addition, the cumulative release values ​​of Example 16 at all time points were significantly lower than those of cisplatin microcrystals (p < 0.05, t-test), for example, at 4 hours, 57 ± 4% and 76 ± 5%, respectively (p < 0.01), indicating a controlled release profile of cisplatin from the composition of the present invention.

[0219] Example 19.-Preparation of budesonide dry powder formulation for inhalation n°4

[0220] 0.1500% w / v budesonide, 2.8215% w / v hydrogenated castor oil (BASF, Ludwigshafen, Germany) (or tristearin for comparative example BUD-TS4) and 0.0285% w / v TPGS (Sigma-Aldrich, St. Louis, USA) were dissolved in hot isopropanol (65°C) under magnetic stirring and the hot solution was spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min of compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0221] Example 20.-Preparation of budesonide dry powder formulation for inhalation n°5

[0222] 0.600% w / v budesonide, 2.376% w / v hydrogenated castor oil (BASF, Ludwigshafen, Germany) (or tristearin for comparative example BUD-TS5) and 0.024% w / v TPGS (Sigma-Aldrich, St. Louis, USA) were dissolved in hot isopropanol (65°C) under magnetic stirring and the hot solution was spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min of compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0223] Example 21.-Preparation of budesonide dry powder formulation for inhalation n°6

[0224] 1.500% w / v budesonide, 1.485% w / v hydrogenated castor oil (BASF, Ludwigshafen, Germany) and 0.015% w / v TPGS (Sigma-Aldrich, St. Louis, USA) were dissolved in hot isopropanol (65°C) under magnetic stirring and the hot solution was spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min of compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0225] Example 22.- Sedimentation rate analysis of budesonide dry powder formulations prepared according to Examples 19 and 20.

[0226] The in vitro lung deposition patterns and fine particle fraction values ​​of the formulations according to Examples 19 and 20 were analyzed. Comparative examples of Formulations 19 and 20 (i.e., BUD-TS4 and BUD-TS5, respectively) were produced according to the same corresponding protocol using tristearin (TS) (Tokyo Chemical Company, Tokyo, Japan) instead of hydrogenated castor oil.

[0227] FPF - which is the percentage of recovered dose related to budesonide-based particles with a dae below 5 μm - and aerodynamic PSD characterized by MMAD were determined using NGI (Copley Scientific, Nottingham, UK) - Apparatus E - as described in European Pharmacopoeia 8.0. (2014). A mass of 10 mg of DPI formulation (according to Examples 19 and 20 and comparative powders BUD-TS4 and BUD-TS5) previously sieved through a 355 mm stainless steel sieve was weighed in a size 3 HPMC capsule (Quali-VI, Qualicaps, Madrid, Spain) and deposited in the NGI using a RS.01 dry powder inhaler (RPC Plastiape, Osnago, Italy) mounted on the inhalation port with its adapter (n=3).

[0228] A deposition flow rate of 100 ± 5 L / min measured using a DFM3 flow meter (Copley Scientific, Nottingham, UK) was obtained with two HCP5 air pumps (Copley Scientific, Nottingham, UK) connected in series to a TPK critical flow controller (Copley Scientific, Nottingham, UK).

[0229] At this flow rate, the cut-off diameters between the stages of the NGI were 6.12, 3.42, 2.18, 1.31, 0.72, 0.40 and 0.24 μm. A critical flow controller was used to ensure a settling time of 2.4 s and a critical flow of P3 / P2 ratio < 0.5 at 100 L / min, as required by European Pharmacopoeia 8.0. (2014).

[0230] After impact, the budesonide material deposited in the capsule, device, inlet, pre-separator, 7 stages and MOC of NGI was collected as the diluent phase with a solution of 0.5% w / v poloxamer 407 in ultrapure water: isopropanol 60:40 (v / v) mixture and ultrasonicated at 60°C for 30 minutes. The solution was then filtered through a 0.45 μm pore size regenerated cellulose Minisart syringe filter (Sartorius Stedim Biotech GmbH, Germany). The impact mass in each stage was determined by quantitative budesonide content by a validated HPLC method. The chromatographic system (HP 1200 series, Agilent Technologies, Diegem, Belgium) was equipped with a quaternary pump, an autosampler and a diode array detector. Separation was performed on a reversed phase Alltima C18 column (5 mm, 150 mm x 4.6 mm) (Hichrom, Theale, UK). The mobile phase consisted of pH=3.20 phosphate buffer: acetonitrile (65:35 v / v) and was delivered at a flow rate of 1.5 mL / min. Quantification was performed at 245 nm. The injection volume was 100 μL, the temperature was set at 40°C, and the analytical run time was 22 minutes.

[0231] The results were then plotted in Copley Inhaler Test Data Analysis Software1 (Copley Scientific, Nottingham, UK) to obtain the FPD below 5 μm. This was done by interpolating the recovered mass with the cut-off diameter of the corresponding stage. The FPF is expressed as a percentage of the nominal dose.

[0232] Figure 8The FPF values ​​of Examples 19 and 20 are shown compared with Comparative Examples BUD-TS4 and BUD-TS5 (mean ± SD, n = 3). (***) p < 0.001, t-test, indicating that the budesonide composition disclosed in the present invention is superior to other triglyceride-based budesonide DPI formulations in terms of lung deposition.

[0233] Example 23.- Dissolution rate of budesonide from budesonide dry powder formulations prepared according to Examples 19, 20 and 21 Rate analysis.

[0234] The dissolution properties of the DPI formulations according to Examples 19, 20 and 21 and comparative budesonide powder (i.e. micronized budesonide) were established by applying a modification of the method described by Pilcer et al. (Pilcer et al., J Pharm Sci 2013). The comparative micronized budesonide powder was prepared by spray drying (Mini-Spray Dryer B-290, Büchi Labortechnik AG, Flavel, Switzerland) a 3% w / v budesonide isopropanol solution to obtain a DPI formulation for human use.

[0235] A dissolution system developed specifically for DPI release profile studies (Copley Scientific, Nottingham, UK) was used, with a method adapted from the "paddle-disc method" (Eur. Ph. 7). In order to study the release profile of particles deposited in the lung, the budesonide formulation was first fractionated using NGI. The cup of stage 2 was selected to be equipped with a removable disk insert to collect particles. Of particular interest, at the selected inhalation rate (100 L / min, 2.4 s), the cutoff diameter of stage 2 was 6.12 μm-3.42 μm, allowing the selection of particles targeted to the lung from capsules filled with an appropriate amount of formulation (according to micronized budesonide and Examples 20, 21 and 22) to deposit approximately 500 μg of budesonide in stage 3. The disk insert was then covered with a polycarbonate membrane (0.4 μm pore size) (Merck Millipore) and placed in a paddle dissolution apparatus (Erweka DT6; ERWEKA GmbH, Heusenstamm, Hesse, Germany) filled with 400 mL 0.01 mM phosphate buffer (PBS), pH 7.4.

[0236] Dissolution testing was performed at 37 ± 0.2 °C, pH 7.35 ± 0.05 according to the water tank conditions. The rotation speed of the paddle (set to 25 ± 2 mm between the paddle and the center of the disk assembly) was set to 50 ± 4 rpm. A sample volume of 2.0 mL was filtered through a 0.22 mm pore size cellulose acetate syringe filter (VWR, Leuven, Belgium) at a predetermined time between 2 minutes and 24 hours and replaced with 2.0 mL free pre-warmed PBS.

[0237] The 100% budesonide dissolution value corresponds to the mass deposited in phase 3.

[0238] Fig. 9 The release profiles of budesonide from the inhalable fraction of the micronized budesonide comparative example and the DPI formulations prepared according to Examples 19, 20 and 21 are shown (n=1), demonstrating the controlled release profile of budesonide from the composition of the present invention and the possibility of adjusting the release profile by adjusting the drug / lipid ratio.

[0239] Example 24.-Preparation of Paclitaxel Dry Powder Formulation for Inhalation n°1

[0240] 0.1500% w / v paclitaxel, 2.8215% w / v hydrogenated castor oil (BASF, Ludwigshafen, Germany) and 0.0285% w / v TPGS (Sigma-Aldrich, St. Louis, USA) were dissolved in hot ethanol (50°C) under magnetic stirring and the hot solution was spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min of compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0241] Example 25.-Preparation of Paclitaxel Dry Powder Formulation for Inhalation n°2

[0242] 0.600% w / v paclitaxel, 2.376% w / v hydrogenated castor oil (BASF, Ludwigshafen, Germany) and 0.024% w / v TPGS (Sigma-Aldrich, St. Louis, USA) were dissolved in hot ethanol (50°C) under magnetic stirring, and the hot solution was spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min of compressed air and 35 m 3The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0243] Example 26.-Preparation of Paclitaxel Dry Powder Formulation for Inhalation n°3

[0244] 1.500% w / v paclitaxel, 1.485% w / v hydrogenated castor oil (BASF, Ludwigshafen, Germany) and 0.015% w / v TPGS (Sigma-Aldrich, St. Louis, USA) were dissolved in hot ethanol (50°C) under magnetic stirring and the hot solution was spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min of compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0245] Example 27.-Preparation of Paclitaxel Dry Powder Formulation for Inhalation n°4

[0246] 2.700% w / v paclitaxel, 0.297% w / v hydrogenated castor oil (BASF, Ludwigshafen, Germany) and 0.003% w / v TPGS (Sigma-Aldrich, St. Louis, USA) were dissolved in hot ethanol (50°C) under magnetic stirring, and the hot solution was spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min of compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0247] Example 28.-Preparation of Paclitaxel Dry Powder Formulation for Inhalation n°5

[0248] 1.50% w / v paclitaxel, 1.35% w / v hydrogenated castor oil (BASF, Ludwigshafen, Germany) and 0.15% w / v TPGS (Sigma-Aldrich, St. Louis, USA) were dissolved in hot ethanol (50°C) under magnetic stirring, and the hot solution was spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min of compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0249] Example 29.-Preparation of Paclitaxel Dry Powder Formulation for Inhalation n°6

[0250] 1.5% w / v paclitaxel, 1.2% w / v hydrogenated castor oil (BASF, Ludwigshafen, Germany) and 0.3% w / v TPGS (Sigma-Aldrich, St. Louis, USA) were dissolved in hot ethanol (50°C) under magnetic stirring, and the hot solution was spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min of compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0251] Example 30.-Preparation of Paclitaxel Dry Powder Formulation for Inhalation n°7

[0252] 1.500% w / v paclitaxel, 1.485% w / v hydrogenated castor oil (BASF, Ludwigshafen, Germany), 0.015% w / v TPGS (Sigma-Aldrich, St. Louis, USA) and 0.3% w / v L-leucine (Sigma-Aldrich) were dissolved in hot ethanol (50°C) under magnetic stirring and the hot solution was spray dried using a Mini-Spray Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland) to obtain a human DPI formulation. The operating parameters used during spray drying were as follows: feed rate 3.0 g / min, inlet temperature 70°C, 0.7 mm nozzle, 1.5 mm nozzle cap, 800 L / min of compressed air and 35 m 3 The apparatus was equipped with a B-296 dehumidifier (Büchi Labortechnik AG) to maintain the relative humidity at 50% HR during spray drying.

[0253] Example 31.-Preparation of budesonide dry powder formulation for inhalation n°7

[0254] First, budesonide dry powder formulation n°4 for inhalation was prepared according to Example 19. Then 10 g of budesonide dry powder formulation n°4 for inhalation and 30 g of lactose ( SV003, DFE Pharma, Goch, Germany) The mixture was mixed in a mixer (Willy A. Bachofen AG, Muttenz, Switzerland) until homogeneous to obtain a carrier-based dry powder formulation for inhalation.

[0255] It will be understood that the invention is not limited to the embodiments described and that variations may be applied without departing from the scope of the appended claims.

Claims

1. A dry powder inhalation formulation comprising an active pharmaceutical ingredient and a lipid matrix, wherein the lipid matrix comprises a triglyceride, and the triglyceride is hydrogenated castor oil; in, The weight of the active pharmaceutical ingredient is 0.1 to 90 wt % relative to the weight of the dry powder inhalation formulation, and The weight ratio of the active pharmaceutical ingredient to the triglyceride is 10 / 90 to 60 / 40.

2. The dry powder inhalation formulation according to claim 1, wherein the weight ratio between the active pharmaceutical ingredient and the triglyceride is 40 / 60 to 60 / 40 relative to the total weight of the dry powder inhalation formulation.

3. The dry powder inhalation formulation according to claim 1, wherein the weight ratio between the active pharmaceutical ingredient and the triglyceride is 50 / 50 relative to the total weight of the dry powder inhalation formulation.

4. The dry powder inhalation formulation according to claim 1, wherein the active pharmaceutical ingredient is a small chemical molecule having a solubility in alcohol of at least 0.1 w% / v.

5. The dry powder inhalation formulation according to claim 1, wherein the active pharmaceutical ingredient is a small chemical molecule having a solubility in alcohol of at least 0.5 w% / v.

6. The dry powder inhalation formulation according to claim 1, wherein the active pharmaceutical ingredient is a small chemical molecule having a solubility in alcohol of at least 1 w% / v.

7. The dry powder inhalation formulation according to claim 1, wherein the active pharmaceutical ingredient is a small chemical molecule having a solubility in alcohol of at least 5 w% / v.

8. The dry powder inhalation formulation according to claim 4, comprising 1 wt% to 85 wt% of the active pharmaceutical ingredient relative to the weight of the dry powder inhalation formulation.

9. The dry powder inhalation formulation according to claim 1, wherein the active pharmaceutical ingredient is a small chemical molecule having a solubility in alcohol of less than 0.5 w% / v.

10. The dry powder inhalation formulation according to claim 1, wherein the active pharmaceutical ingredient is a small chemical molecule having a solubility in alcohol of less than 0.1 w% / v.

11. The dry powder inhalation formulation according to claim 1, wherein the active pharmaceutical ingredient is a small chemical molecule having a solubility in alcohol of less than 0.01 w% / v.

12. The dry powder inhalation formulation according to claim 9, comprising 1 wt% to 90 wt% of the active pharmaceutical ingredient relative to the weight of the dry powder inhalation formulation.

13. The dry powder inhalation formulation according to claim 9, comprising 1 wt% to 85 wt% of the active pharmaceutical ingredient relative to the weight of the dry powder inhalation formulation.

14. The dry powder inhalation formulation of claim 1, wherein the active pharmaceutical ingredient is a macromolecule.

15. The dry powder inhalation formulation according to claim 14, comprising 1 wt% to 90 wt% of the active pharmaceutical ingredient relative to the weight of the dry powder inhalation formulation.

16. The dry powder inhalation formulation according to claim 14, comprising 1 wt% to 85 wt% of the active pharmaceutical ingredient relative to the weight of the dry powder inhalation formulation.

17. The dry powder inhalation formulation according to any one of claims 1 to 16, further comprising an excipient that prolongs lung retention.

18. The dry powder inhalation formulation according to claim 17, wherein the excipient is a pegylated excipient or a polysaccharide.

19. The dry powder inhalation formulation according to claim 17, wherein the excipient is chitosan or dextran.

20. The dry powder inhalation formulation according to claim 17, wherein the extended lung retention excipient is a pegylated excipient and is present in an amount of 0.1 wt% to 20 wt% relative to the total weight of the dry powder inhalation formulation.

21. The dry powder inhalation formulation according to claim 17, wherein the extended lung retention excipient is a pegylated excipient and is present in an amount of 0.2 wt% to 10 wt% relative to the total weight of the dry powder inhalation formulation.

22. The dry powder inhalation formulation according to claim 17, wherein the extended lung retention excipient is a pegylated excipient and is present in an amount of 0.5 wt% to 5 wt% relative to the total weight of the dry powder inhalation formulation.

23. The dry powder inhalation formulation of claim 18, wherein the pegylated excipient is derived from vitamin E or a phospholipid.

24. The dry powder inhalation formulation of claim 18, wherein the PEGylated excipient is derived from tocopheryl polyethylene glycol succinate or distearoyl phosphoethanolamine polyethylene glycol 2000.

25. The dry powder inhalation formulation of claim 1, wherein the formulation is a formulation having a geometric particle size distribution d of less than or equal to 30 μm. 50 in the form of fine particles.

26. The dry powder inhalation formulation of claim 1, wherein the formulation is a formulation having a geometric particle size distribution d of less than 15 μm. 50 in the form of fine particles.

27. The dry powder inhalation formulation of claim 1, wherein the formulation is a formulation having a geometric particle size distribution d of less than or equal to 10 μm. 50 in the form of fine particles.

28. The dry powder inhalation formulation of claim 1, wherein the formulation is a formulation having a geometric particle size distribution d of less than or equal to 5 μm. 50 in the form of fine particles.

29. The dry powder inhalation formulation of claim 1, wherein the formulation is a formulation having a geometric particle size distribution d of less than or equal to 60 μm. 90 in the form of fine particles.

30. The dry powder inhalation formulation of claim 1, wherein the formulation has a geometric particle size distribution d of less than or equal to 30 μm. 90 in the form of fine particles.

31. The dry powder inhalation formulation of claim 1, wherein the formulation is a formulation having a geometric particle size distribution d of less than or equal to 15 μm. 90 in the form of fine particles.

32. The dry powder inhalation formulation of claim 1, wherein the formulation is a formulation having a geometric particle size distribution d of less than or equal to 10 μm. 90 in the form of fine particles.

33. The dry powder inhalation formulation of claim 1, wherein the formulation is a formulation having a geometric particle size distribution d of less than or equal to 7 μm. 90 in the form of fine particles.

34. The dry powder inhalation formulation of claim 1, wherein the formulation is in the form of particles having a volume mean diameter D[4,3] less than or equal to 40 μm.

35. The dry powder inhalation formulation of claim 1, wherein the formulation is in the form of particles having a volume mean diameter D[4,3] less than or equal to 20 μm.

36. The dry powder inhalation formulation of claim 1, wherein the formulation is in the form of particles having a volume mean diameter D[4,3] less than or equal to 15 μm.

37. The dry powder inhalation formulation of claim 1, wherein the formulation is in the form of particles having a volume mean diameter D[4,3] less than or equal to 10 μm.

38. The dry powder inhalation formulation of claim 1, wherein the formulation is in the form of particles having a volume mean diameter D[4,3] less than or equal to 6 μm.

39. The dry powder inhalation formulation according to claim 1, further comprising an excipient that improves physicochemical and / or aerodynamic properties, present in an amount of 0.1 wt% to 80 wt% relative to the total weight of the dry powder inhalation formulation.

40. The dry powder inhalation formulation of claim 1 in the form of fine particles having a mass median aerodynamic diameter of less than or equal to 6 μm.

41. The dry powder inhalation formulation of claim 1 in the form of fine particles having a mass median aerodynamic diameter of less than or equal to 5 μm.

42. The dry powder inhalation formulation of claim 1 in the form of fine particles having a mass median aerodynamic diameter of less than or equal to 4 μm.

43. The dry powder inhalation formulation according to claim 1 in blisters or capsules for use in a dry powder inhaler or a sealed and / or disposable dry powder inhaler.

44. The dry powder inhalation formulation of claim 1, wherein the active pharmaceutical ingredient is a small chemical molecule having bronchodilator activity, glucocorticoid activity, anti-inflammatory activity, or anti-infective activity.

45. The dry powder inhalation formulation of claim 1, wherein the active pharmaceutical ingredient is any active pharmaceutical ingredient that is absorbed by the lungs for systemic or local treatment.

46. ​​The dry powder inhalation formulation of claim 1, wherein the active pharmaceutical ingredient is budesonide, salbutamol, fluticasone, beclomethasone, mometasone, ciclesonide, formoterol, arformoterol, indacaterol, olodaterol, salmeterol, ipratropium, aclidinium, glycopyrronium, tiotropium, umeclidinium, mometasone, ibuprofen, tobramycin, vancomycin, tetrahydrolipril, clarithromycin, isoniazid, rifampicin, pyrazinamide, itraconazole, voriconazole, aztreonam, ethambutol, Streptomycin, kanamycin, amikacin, colistin, polymyxin E mesylate sodium, streptomycin, ciprofloxacin, rifapentine, doxycycline, cycloserine E, ethionamide, gatifloxacin, levofloxacin, moxifloxacin, ofloxacin, fosfomycin, para-aminosalicylate, denofosol tetrasodium, lancovirtide, ribavirin, zanamivir, laminavir, rubisvir, pentamidine, amphotericin B, posaconazole, isavuconazole, caprafungin, micafungin, anidulafungin, iloprost, or levothyroxine.

47. The dry powder inhalation formulation of claim 14, wherein the macromolecule is a peptide, a protein, an antibody, an antibody fragment, a nanobody, a nucleic acid.

48. The dry powder inhalation formulation of claim 14, wherein the macromolecule is insulin, proinsulin, synthetic insulin, semi-synthetic insulin, bevacizumab, pembrolizumab, atezolizumab, nivolumab, ipilimumab, toll-like receptor agonist, growth hormone releasing peptide, IgG monoclonal antibody, small interfering RNA, dornase alfa, cyclosporine A, alpha-1 antitrypsin, interleukin antagonist, interferon-alpha, interferon-beta, interferon-gamma, interferon-omega, interleukin-2, anti-IgE mAb, catalase, calcitonin, parathyroid hormone, human growth hormone, insulin-like growth factor-I, heparin, rhG-CSF, GM-CSF, Epo-Fc, FSH-Fc, sFc-gammaRIIb, mRNA.

49. The dry powder inhalation formulation of claim 1, wherein the active pharmaceutical ingredient is an anti-neoplastic agent.

50. The dry powder inhalation formulation according to claim 49, wherein the anti-tumor agent is cisplatin, carboplatin, oxaliplatin, docetaxel, paclitaxel, pemetrexed, etoposide, vinorelbine.

51. The dry powder inhalation formulation according to claim 1, which is in the form of an oral dry powder inhalation formulation.